A placebo-controlled trial of obeticholic acid in primary biliary cholangitis F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ... New England Journal of Medicine 375 (7), 631-643, 2016 | 1098 | 2016 |
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years DC Klonoff, JB Buse, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ... Current medical research and opinion 24 (1), 275-286, 2008 | 1041 | 2008 |
Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases KD Lindor, CL Bowlus, J Boyer, C Levy, M Mayo Hepatology 69 (1), 394-419, 2019 | 722 | 2019 |
Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ... Gastroenterology 152 (8), 1975-1984. e8, 2017 | 473 | 2017 |
Primary biliary cirrhosis C Selmi, CL Bowlus, ME Gershwin, RL Coppel The Lancet 377 (9777), 1600-1609, 2011 | 442 | 2011 |
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ... Nature genetics 45 (6), 670-675, 2013 | 431 | 2013 |
Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis RY Lan, C Cheng, ZX Lian, K Tsuneyama, GX Yang, Y Moritoki, ... Hepatology 43 (4), 729-737, 2006 | 362 | 2006 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open … JB Buse, DC Klonoff, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ... Clinical therapeutics 29 (1), 139-153, 2007 | 360 | 2007 |
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease SG Ji, BD Juran, S Mucha, T Folseraas, L Jostins, E Melum, N Kumasaka, ... Nature genetics 49 (2), 269-273, 2017 | 315 | 2017 |
Biliary apotopes and anti‐mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis A Lleo, CL Bowlus, GX Yang, P Invernizzi, M Podda, J Van de Water, ... Hepatology 52 (3), 987-998, 2010 | 248 | 2010 |
IL‐12/Th1 and IL‐23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy CY Yang, X Ma, K Tsuneyama, S Huang, T Takahashi, NP Chalasani, ... Hepatology 59 (5), 1944-1953, 2014 | 226 | 2014 |
The diagnosis of primary biliary cirrhosis CL Bowlus, ME Gershwin Autoimmunity reviews 13 (4-5), 441-444, 2014 | 212 | 2014 |
Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid M Tsuda, Y Moritoki, ZX Lian, W Zhang, K Yoshida, K Wakabayashi, ... Hepatology 55 (2), 512-521, 2012 | 211 | 2012 |
The nonsteroidal farnesoid X receptor agonist cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis M Trauner, A Gulamhusein, B Hameed, S Caldwell, ML Shiffman, ... Hepatology 70 (3), 788-801, 2019 | 206 | 2019 |
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis CA Aoki, CM Roifman, ZX Lian, CL Bowlus, GL Norman, Y Shoenfeld, ... Journal of autoimmunity 27 (1), 50-53, 2006 | 199 | 2006 |
De novo nonalcoholic fatty liver disease after liver transplantation S Seo, K Maganti, M Khehra, R Ramsamooj, A Tsodikov, C Bowlus, ... Liver Transplantation 13 (6), 844-847, 2007 | 194 | 2007 |
DMT1 gene expression and cadmium absorption in human absorptive enterocytes J Tallkvist, CL Bowlus, B Lönnerdal Toxicology letters 122 (2), 171-177, 2001 | 181 | 2001 |
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised … D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ... The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017 | 163 | 2017 |
The geoepidemiology of autoimmune intestinal diseases I Logan, CL Bowlus Autoimmunity reviews 9 (5), A372-A378, 2010 | 160 | 2010 |
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study M Trauner, F Nevens, ML Shiffman, JPH Drenth, CL Bowlus, V Vargas, ... The Lancet Gastroenterology & Hepatology 4 (6), 445-453, 2019 | 157 | 2019 |